Will focal therapy become a standard of care for men with localized prostate cancer?
about
High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series.Transrectal high-intensity focused ultrasound for the treatment of prostate cancer: past, present, and future.Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development studyFocal therapy for prostate cancer: rationale and treatment opportunities.Prostate cancer tumour features on template prostate-mapping biopsies: implications for focal therapySelective nanoparticle-directed ablation of the canine prostate.The role of focal therapy in the management of localised prostate cancer: a systematic review.Photodynamic therapy for photochemists.Nanoparticle-Enabled Selective Destruction of Prostate Tumor Using MRI-Guided Focal Photothermal Therapy.An update on focal therapy for prostate cancer.Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study.Focal Cryotherapy in Low-Risk Prostate Cancer: Are We Treating the Cancer or the Mind? - The Cancer.Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancerImaging and Markers as Novel Diagnostic Tools in Detecting Insignificant Prostate Cancer: A Critical OverviewDosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy.Combination of clinical characteristics and transrectal ultrasound-guided biopsy to predict lobes without significant cancer: application in patient selection for hemiablative focal therapy.Is focal therapy the future for prostate cancer?Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer.Patterns of outcome and toxicity after salvage prostatectomy, salvage cryosurgery and salvage brachytherapy for prostate cancer recurrences after radiation therapy: a multi-center experience and literature review.Advances in oncologic imaging: update on 5 common cancers.Health technology assessment in evolution - focal therapy in localised prostate cancer.Pros and cons of focal therapy for localised prostate cancer.Percutaneous MR-guided focal cryoablation for recurrent prostate cancer following radiation therapy: retrospective analysis of iceball margins and outcomesAnatomically versus biologically unifocal prostate cancer: a pathological evaluation in the context of focal therapy.Investigation of power and frequency for 3D conformal MRI-controlled transurethral ultrasound therapy with a dual frequency multi-element transducer.Identifying the dominant prostate cancer focal lesion using image analysis and planning of a simultaneous integrated stereotactic boost.Radical prostatectomy specimens - a voice against focal therapy.Focal salvage therapy for localized prostate cancer recurrence after external beam radiotherapy: a pilot study.Outcome of repeated prostatic biopsy during active surveillance: implications for focal therapy.Prognostic value of preoperative multiparametric magnetic resonance imaging (MRI) for predicting biochemical recurrence after radical prostatectomy.Can we deliver randomized trials of focal therapy in prostate cancer?Prostate cancer: utility of fusion of T2-weighted and high b-value diffusion-weighted images for peripheral zone tumor detection and localization.Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.The prostate cancer focal therapy.Reply to S Eggener, M Gonzalgo and O Yossepowitch: ‘High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series'.A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer
P2860
Q30480603-B62B1BA4-D74D-4B56-B7D3-C7546C19EFC4Q30481118-7549798D-B5B2-4EEB-B02B-EF799C2D130FQ30514532-AE570E7E-1FB1-4A34-8402-1804CDCEFB15Q33702259-BE292397-ADA7-4F43-BF67-283649352F08Q33775669-05D40C4A-0258-40BF-9306-E5A6141B424CQ33849097-F77D400C-71E3-4B62-BDA0-25029BBBF1D2Q34266167-ED9F3256-3F59-48AA-83E6-6B47881035FFQ34775481-00B8D67D-40A8-43A8-BE90-87020A4231DAQ36023165-A1564574-656B-48CE-B0EF-07DCD30E8023Q36145325-8D24AFA5-80D2-42D8-89FE-A57493D06D67Q36346204-ABBC59D0-F918-4592-8BE6-88EBA0E48A82Q36575721-BD3CDD17-3D12-40D9-8FAB-BA2E5A7915DFQ36928846-8B8D5394-8E6A-4097-BD8A-D1ECCF8FB7AFQ36979944-D60BE0CE-0BFE-40ED-919E-B664F215BC64Q37175207-34FCD992-2129-41DF-A260-D7969FAADD86Q37676133-FC862E51-536A-4EC6-8E62-DBBED64A3041Q37690305-C5B7904D-4140-4060-9FB5-939E623B23B4Q37768769-3850BB5C-E052-4601-B735-F6A367407F5CQ38035794-F4708452-015B-4B55-99D4-2A68B1548FEEQ38052458-E0818C50-2EA1-43E4-BEF4-33B854C5864DQ38223247-336F8B0F-8946-4863-8A0C-94B5D6E0E939Q38807805-62196B6D-76E8-48FD-9B51-FAED2DD9DD62Q38837262-FD6AD3D1-DAB8-46FA-BDE9-86422972D69FQ39576290-5C7D726C-668D-4E9C-A74A-C2A06739338DQ39665631-9AE34FDA-F554-425A-A328-00769587D407Q40511771-D4441658-58A8-45F6-ADF0-5EEBEA7A564FQ41867844-2C90CE58-87B1-4B7E-9C1B-375BDF55E126Q45937049-0E7F45E7-74A6-4E1D-A6BE-3D335EEA25EBQ46669909-B0E3315E-8178-4E7A-9D8F-B6BF113D5A7BQ47796911-C17CEF89-D36E-4BDD-BE3B-A94E527A27D6Q50243071-1D5AAB75-21FF-42DE-974B-1D3DBF804A29Q51555022-06C290E1-FFDF-4650-9275-D76A917C4CC9Q53091492-73856E1E-5164-416E-A08B-BF8AC932A705Q54996559-4F6E1264-9B64-4636-AED5-D74163FC6974Q55068732-DFC32D79-46F7-4570-8A54-3A22BF37777EQ58794132-5F464B76-6DC5-4A1D-9644-65798FD908E5
P2860
Will focal therapy become a standard of care for men with localized prostate cancer?
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Will focal therapy become a standard of care for men with localized prostate cancer?
@en
type
label
Will focal therapy become a standard of care for men with localized prostate cancer?
@en
prefLabel
Will focal therapy become a standard of care for men with localized prostate cancer?
@en
P2093
P356
P1476
Will focal therapy become a standard of care for men with localized prostate cancer?
@en
P2093
Clare Allen
Doug Pendse
Hashim Uddin Ahmed
Jan H P van der Meulen
Rowland Illing
P2860
P304
P356
10.1038/NCPONC0959
P577
2007-11-01T00:00:00Z